EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Atossa Therapeutics's enterprise value is $99.50 Mil.
Atossa Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-31.36 Mil. Therefore, Atossa Therapeutics's EV-to-EBITDA for today is -3.17.
The historical rank and industry rank for Atossa Therapeutics's EV-to-EBITDA or its related term are showing as below:
ATOS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.91 Med: 0.46 Max: 0.55
Current: -3.17
During the past 13 years, the highest EV-to-EBITDA of Atossa Therapeutics was 0.55. The lowest was -15.91. And the median was 0.46.
ATOS's EV-to-EBITDA is ranked worse than 100% of 473
companies
in the Biotechnology industry
Industry Median: 9.22
vs ATOS: -3.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Atossa Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Atossa Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Atossa Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Atossa Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atossa Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Atossa Therapeutics's EV-to-EBITDA falls into.
Atossa Therapeutics's current Enterprise Value is $99.50 Mil.
Atossa Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Atossa Therapeutics's PE Ratio for today is calculated as:
Atossa Therapeutics's share price for today is $1.52.
Atossa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Atossa Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Atossa Therapeutics (Atossa Therapeutics) Business Description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATOS has been successfully added to your 